DNTH
Dianthus Therapeutics Inc.
NASDAQ: DNTH · HEALTHCARE · BIOTECHNOLOGY
$87.12
+0.47% today
Updated 2026-05-11
Market cap
$4.76B
P/E ratio
—
P/S ratio
3,564.76x
EPS (TTM)
$-4.23
Dividend yield
—
52W range
$17 – $97
Volume
1.0M
Dianthus Therapeutics Inc. (DNTH) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-6.53M | $-22.26M | $-41.89M | $-57.10M | $-64.02M | $-59.53M | $-29.07M | $-36.86M | $-78.18M | $-129.06M |
| Capital expenditures | $139000.00 | $2.20M | $7.67M | $3.06M | $400000.00 | $1.26M | $139000.00 | $110000.00 | $105000.00 | $213000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $662000.00 | $2.26M | $10.70M | $10.00M | $9.94M | $63000.00 | $1.52M | $2.90M | $12.89M | $22.79M |
| Free cash flow | $-6.67M | $-24.46M | $-49.56M | $-60.16M | $-64.42M | $-60.80M | $-29.21M | $-36.97M | $-78.28M | $-129.27M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — |